|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||1.5700 - 1.5900|
|52-week range||1.5700 - 1.5900|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.
A look at the shareholders of Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ) can tell us which group is most powerful...